On January 27, 2023, Tito Serafini, PhD, Chief Strategy Officer at Atreca, presented the company in an Emerging Therapeutics Showcase at the Precision Medicine World Conference (PMWC 2023) (January 25-27). The title of his presentation was “Delivering the Potential of Immunotherapy.” Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its unique discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as the company’s lead product candidate ATRC-101, its pipeline of lead-stage oncology programs, and MAM01/ATRC-501, a clinical candidate licensed to the Bill & Melinda Gates Medical Research Institute for the prevention of malaria.
Atreca Presents Novel Immunotherapy Approach at Precision Medicine World Conference (PMWC 2023); Complete Remission of Metastatic Melanoma Highlighted
Login Or Register To Read Full Story